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The pathogenesis of solid tumors is a long-term process 
involving the accumulation of multiple genetic and 
epigenetic changes causing activation of oncogenes and 
inactivation of tumor suppressor genes. Gene amplification is 
one of the most common causes of oncogene activation that 
plays a critical role in the development and progression of 
various cancers because over expression of candidate 
oncogene(s) within the amplicon confers a selective growth 
advantage. Amplification of the long arm of chromosome 3, 
especially 3q26, is one of the most frequently detected 
genomic alterations in various cancers, such as lung cancer 
[1, 
2]
, esophageal carcinoma 
[3]
, breast cancer 
[4]
, ovarian cancer 
[5]
 and nasopharyngeal carcinoma 
[6]
, suggesting the existence 
of one or more important oncogenes at 3q26. To identify 
candidate oncogene(s) within the 3q26 amplicon, genomic 
DNA library of 3q26 was generated by chromosome micro 
dissection and a hybrid selection strategy was applied to 
isolate over expressed genes from the micro dissected DNA 
[7]
. One candidate oncogene at 3q26, eukaryotic translation 
initiation factor 5A2 (eIF5A2) was identified by this strategy. 
In the same time, Johansson and his colleagues also 
identified eIF5A2 as a phylogenetically conserved variant of 
eIF5A 
[8]
. EIF5A2 shares 83% amino acid identity with 
EIF5A including the critical functional domain necessary for 
maturation by hypusine modification at lysine-50 residue 
[7, 9, 
10]
. Unlike EIF5A that is universally expressed in tissues, 
EIF5A2 is only found in testis, brain and tumor tissues 
[8]
.  
Since eIF5A2 was firstly reported to be amplified in 
ovarian cancer 
[7]
, overexpression of eIF5A2 has been 
reported in many other solid tumors including hepatocellular 
carcinoma (HCC) 
[10, 11]
, esophageal squamous cell 
carcinoma (ESCC) 
[12]
, gastric cancer 
[13]
, non-small cell lung 
cancer 
[2]
, bladder cancer 
[14, 15]
, melanoma
[16]
 and colorectal 
cancer 
[17, 18]
. Interestingly, overexpression of eIF5A2 has 
been closely associated with clinical stage and tumor 
metastasis in several cancers including ovarain cancer 
[19]
, 
melanoma 
[16]
, colorectal cancer 
[18]
 and HCC 
[10]
. In addition, 
overexpression of eIF5A2 has been also closely correlated 
with poorer outcome of several cancers, such as ovarian 
cancer 
[20]
, bladder cancer 
[15]
, ESCC 
[12]
 and pancreatic 
cancer 
[21]
. Metastasis consists of a series of rate limiting 
steps. Metastasis is the acquisition of motility by tumor cells 
in a process: epithelial-mesenchymal transition (EMT). 
Recent studies have demonstrated that eIF5A2 plays an 
important role in EMT through the down-regulation of 
epithelial markers (e.g. E-cadherin and β-catenin) and 
up-regulation of mesenchymal markers (e.g. fibronectin and 
vimentine) 
[10, 12]
. In addition, these studies find that 
overexpression of eIF5A2 is able to promote the formation of 
stress fiber and lamellipodia via the activation of RhoA/Rac1 
signaling pathway
 [10, 12]
. Molecular studies indicate that 
eIF5A2 is able to promote tumor metastasis by enhancing the 
binding of c-myc on MTA1 promoter 
[18]
, to induce EMT via 
activating STAT3/ TGF-β1 signaling
[15]
 and to increase 
MMP-2 activity 
[16]
. 
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Although 3q26 amplification is a major event for eIF5A2 
over expression in ovarian cancer 
[7]
, amplification of 3q26 
has not been frequently detected in many other cancers, such 
as HCC 
[22]
. In ESCC, the copy number gain was detected in 
less than 40% of ESCCs with eIF5A2 over expression 
[12]
, 
suggesting that other mechanisms might contribute to the 
eIF5A2 over expression event. Further study finds that 
eIF5A2 expression can be induced by hypoxic culture 
condition 
[12]
. Hypoxia is a powerful driving force to 
breakdown normal tissue homeostasis and rearrangement of 
tumor-stroma interactions in tumor invasion and metastasis 
[23]
. Hypoxia-inducible factor-1 (HIF1) is one of the best 
characterized hypoxia response pathways. HIF1α is one of 
the master regulators of tumor metastasis, which can be 
regulated through oxygen-dependent and -independent 
mechanisms in a cell specific manner 
[24]
. Our study 
demonstrated that bidirectional regulation exists between 
EIF5A2 and HIF1α 
[12]
. The direct binding of EIF5A2 to the 
promoter region of HIF1α has been verified by luciferase 
assay and chromatin immunoprecipitation 
[12]
. Since HIF1α 
also plays a very important role in tumor angiogenesis, the 
association of EIF5A2 over expression and angiogenesis has 
been studied. The results demonstrate that over expression of 
EIF5A2 can promote angiogenesis, and association study on 
clinical ESCC specimens indicates that over expression of 
EIF5A2 is positively correlated with HIF1α and VEGF 
expressions 
[12]
. In HCC, eIF5A2 has been reported to be 
associated with venous infiltration too 
[25]
.  
eIF5A2 has been associated with chemo resistance in 
breast cancer 
[26]
, therefore, it is a potential therapeutic target 
for cancer treatment. shRNAs targeting eIF5A2 along or with 
the combination of chemotherapeutic agent docetaxel (TXT) 
or cisplatin (CDDP) can effectively reduce the tumor volume 
and tumor weight in animal models 
[12]
. Inhibiting eIF5A2 
activity with N1-guanyl-1, 7-diaminoheptane (GC7) has 
demonstrated to enhance the therapeutic efficacy of 
doxorubicin in HCC and bladder cancer cells 
[27, 28]
. As 
eIF5A2 plays an important role in the multi-step progression 
of metastasis and angiogenesis, therapeutic targeting eIF5A2 
may become a new useful approach to prevent and/or control 
tumor metastasis and angiogenesis in cancer treatment. 
Taken together, recent studies have demonstrated that 
eIF5A2 plays critical roles in tumor cell proliferation, 
invasion, metastasis, angiogenesis and drug resistance. As 
silencing eIF5A2 expression can dramatically inhibit its 
oncogenic function, targeting this oncogene might shed light 
on the effective treatment of cancer patients with eIF5A2 
over expression. 
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